Degradation by design
76Bio aims to develop transformational therapies for patients with life-threatening disease by pioneering the next generation of targeted protein degraders.
76Bio
Meet our Team
Management
Sean Algeo, CPA
Controller & Treasurer
Kerry Benenato, PhD
Chief Scientific Officer
Marius Pop, PhD
VP Biology
Alexandra Snyder
VP Clinical Translation
Nicole van de Leuv
VP Legal
Christopher Wilfong
President & CEO
Scientific Advisors, Directors and Co-founders
Arie Belldegrun, MD
Bellco Capital
Joshua Kazam
Two River
Angela Koehler, PhD
MIT
Charles Lin, PhD
Kronos Bio
David Tanen
Two River
Owen Witte, MD
UCLA
K. Dane Wittrup, PhD
MIT
